REPRISE Study Results and Expert Reactions

The REPRISE study was conducted in late-stage ADPKD patients with chronic kidney disease as part of the tolvaptan clinical development program. It enrolled over 1,300 patients from 213 centres across 21 countries, including 6 centres in Canada. The results of the REPRISE study were announced on November 4 at the ASN Kidney Week 2017 in New Orleans. The REPRISE Study already appears in the New England Journal of Medicine with an accompanying editorial ( Article, Editorial). 

Dr. Louis Girard
Clinical Associate Professor
University of Calgary
Nephrologist
Division of Nephrology
Foothills Hospital
Calgary, Alberta, Canada

Dr. Daniel Bichet
Professor of Medicine and Molecular & Integrative Physiology
University of Montreal
Nephrologist
Sacré-Coeur de Montréal Hospital
Montreal, Quebec, Canada

Dr. Daniel Sapir
Medical Director of Hemodialysis
Nephrologist
Halton Healthcare Services
Oakville, Ontario Canada